See more : eHealth, Inc. (EHTH) Income Statement Analysis – Financial Results
Complete financial analysis of Bio-Rad Laboratories, Inc. (BIO) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Bio-Rad Laboratories, Inc., a leading company in the Medical – Devices industry within the Healthcare sector.
You may be interested
- The Brink’s Company (BCO) Income Statement Analysis – Financial Results
- Orrön Energy AB (publ) (LUNE.ST) Income Statement Analysis – Financial Results
- Supriya Lifescience Limited (SUPRIYA.BO) Income Statement Analysis – Financial Results
- Skåne-möllan AB (publ) (SKMO.ST) Income Statement Analysis – Financial Results
- Puxin Limited (NEW) Income Statement Analysis – Financial Results
Bio-Rad Laboratories, Inc. (BIO)
About Bio-Rad Laboratories, Inc.
Bio-Rad Laboratories, Inc. manufactures, and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. The company operates through Life Science and Clinical Diagnostics segments. The Life Science segment develops, manufactures, and markets a range of reagents, apparatus, and laboratory instruments that are used in research techniques, biopharmaceutical production processes, and food testing regimes. It focuses on selected segments of the life sciences market in proteomics, genomics, biopharmaceutical production, cellular biology, and food safety. This segment serves universities and medical schools, industrial research organizations, government agencies, pharmaceutical manufacturers, biotechnology researchers, food producers, and food testing laboratories. The Clinical Diagnostics segment designs, manufactures, sells, and supports test systems, informatics systems, test kits, and specialized quality controls for clinical laboratories in the diagnostics market. This segment offers reagents, instruments, and software, which address specific niches within the in vitro diagnostics test market. It sells its products to reference laboratories, hospital laboratories, state newborn screening facilities, physicians' office laboratories, and transfusion laboratories. In addition, the company offers products and systems to separate complex chemical and biological materials, as well as to identify, analyze, and purify components. The company offers its products through its direct sales force, as well as through distributors, agents, brokers, and resellers. Bio-Rad Laboratories, Inc. was founded in 1952 and is headquartered in Hercules, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 | 1995 | 1994 | 1993 | 1992 | 1991 | 1990 | 1989 | 1988 | 1987 | 1986 | 1985 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 2.67B | 2.80B | 2.92B | 2.55B | 2.31B | 2.29B | 2.16B | 2.07B | 2.02B | 2.18B | 2.13B | 2.07B | 2.07B | 1.93B | 1.78B | 1.76B | 1.46B | 1.27B | 1.18B | 1.09B | 1.00B | 892.72M | 817.51M | 725.88M | 549.50M | 441.90M | 426.90M | 418.80M | 396.60M | 355.30M | 328.60M | 330.30M | 310.70M | 286.70M | 236.30M | 198.90M | 159.50M | 126.60M | 102.30M |
| Cost of Revenue | 1.24B | 1.23B | 1.28B | 1.11B | 1.05B | 1.07B | 972.75M | 930.09M | 897.77M | 996.53M | 954.22M | 908.19M | 895.64M | 835.63M | 784.40M | 801.84M | 669.69M | 561.39M | 534.50M | 479.94M | 437.99M | 383.24M | 356.33M | 300.06M | 227.70M | 181.50M | 169.90M | 164.10M | 155.20M | 139.00M | 134.40M | 124.30M | 122.20M | 113.30M | 95.30M | 81.50M | 63.50M | 52.70M | 45.60M |
| Gross Profit | 1.43B | 1.57B | 1.64B | 1.44B | 1.26B | 1.22B | 1.19B | 1.14B | 1.12B | 1.18B | 1.18B | 1.16B | 1.18B | 1.09B | 999.84M | 962.52M | 791.36M | 712.54M | 646.49M | 610.07M | 565.39M | 509.49M | 461.18M | 425.83M | 321.80M | 260.40M | 257.00M | 254.70M | 241.40M | 216.30M | 194.20M | 206.00M | 188.50M | 173.40M | 141.00M | 117.40M | 96.00M | 73.90M | 56.70M |
| Gross Profit Ratio | 53.58% | 55.93% | 56.14% | 56.48% | 54.38% | 53.46% | 54.97% | 55.03% | 55.54% | 54.18% | 55.26% | 56.11% | 56.81% | 56.64% | 56.04% | 54.55% | 54.16% | 55.93% | 54.74% | 55.97% | 56.35% | 57.07% | 56.41% | 58.66% | 58.56% | 58.93% | 60.20% | 60.82% | 60.87% | 60.88% | 59.10% | 62.37% | 60.67% | 60.48% | 59.67% | 59.02% | 60.19% | 58.37% | 55.43% |
| Research & Development | 226.93M | 256.89M | 271.66M | 226.60M | 202.71M | 199.20M | 250.30M | 205.86M | 192.97M | 220.33M | 210.95M | 214.04M | 186.44M | 172.27M | 163.59M | 159.52M | 140.54M | 123.38M | 115.10M | 108.34M | 94.27M | 82.94M | 76.54M | 68.14M | 51.20M | 41.40M | 46.10M | 39.60M | 34.70M | 30.20M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 834.78M | 808.94M | 816.72M | 761.99M | 808.20M | 798.07M | 682.90M | 696.29M | 0.00 | 601.47M | 591.30M | 507.98M | 438.95M | 416.08M | 378.26M | 325.36M | 289.18M | 272.61M | 247.61M | 194.50M | 167.00M | 164.80M | 155.50M | 150.30M | 132.60M | 167.20M | 177.60M | 154.30M | 138.70M | 112.00M | 91.20M | 74.50M | 58.70M | 46.00M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -1.49M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 820.62M | 827.83M | 879.57M | 800.27M | 824.63M | 833.29M | 808.94M | 816.72M | 761.99M | 808.20M | 798.07M | 682.90M | 696.29M | 635.21M | 601.47M | 591.30M | 507.98M | 438.95M | 416.08M | 378.26M | 325.36M | 289.18M | 272.61M | 247.61M | 194.50M | 167.00M | 164.80M | 155.50M | 150.30M | 132.60M | 167.20M | 177.60M | 154.30M | 138.70M | 112.00M | 91.20M | 74.50M | 58.70M | 46.00M |
| Other Expenses | 0.00 | 44.57M | 26.78M | 24.49M | 26.09M | 36.59M | 12.20M | 14.85M | 11.08M | 13.01M | 12.77M | 21.78M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 43.31M | 27.50M | 21.00M | 19.50M | 17.90M | 16.70M | 16.80M | 16.60M | 13.90M | 12.10M | 10.30M | 7.90M | 6.40M | 5.10M | 3.30M | 2.00M |
| Operating Expenses | 1.09B | 1.08B | 1.15B | 1.03B | 1.03B | 1.03B | 1.06B | 1.02B | 954.96M | 1.03B | 1.01B | 896.94M | 882.73M | 807.48M | 765.05M | 808.34M | 648.51M | 562.33M | 531.19M | 486.61M | 419.63M | 372.11M | 349.15M | 359.06M | 273.20M | 229.40M | 230.40M | 213.00M | 201.70M | 179.60M | 183.80M | 191.50M | 166.40M | 149.00M | 119.90M | 97.60M | 79.60M | 62.00M | 48.00M |
| Cost & Expenses | 2.29B | 2.32B | 2.43B | 2.13B | 2.08B | 2.10B | 2.03B | 1.95B | 1.85B | 2.03B | 1.96B | 1.81B | 1.78B | 1.64B | 1.55B | 1.61B | 1.32B | 1.12B | 1.07B | 966.55M | 857.62M | 755.35M | 705.48M | 659.12M | 500.90M | 410.90M | 400.30M | 377.10M | 356.90M | 318.60M | 318.20M | 315.80M | 288.60M | 262.30M | 215.20M | 179.10M | 143.10M | 114.70M | 93.60M |
| Interest Income | 100.90M | 58.00M | 18.90M | 18.20M | 30.50M | 26.60M | 19.10M | 14.70M | 10.10M | 13.50M | 13.40M | 11.40M | 8.20M | 5.20M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 49.44M | 38.11M | 1.55M | 21.86M | 23.42M | 23.96M | 21.91M | 21.94M | 21.69M | 22.13M | 61.27M | 49.26M | 53.14M | 63.72M | 47.02M | 32.11M | 31.61M | 32.02M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 145.90M | 177.20M | 176.90M | 175.20M | 174.50M | 138.10M | 148.70M | 142.90M | 131.85M | 149.89M | 147.16M | 130.42M | 120.96M | 108.91M | 101.68M | 97.09M | 67.30M | 55.40M | 61.00M | 56.20M | 42.00M | 38.00M | 41.30M | 43.31M | 27.50M | 21.00M | 19.50M | 17.90M | 16.70M | 16.80M | 16.60M | 13.90M | 12.10M | 10.30M | 7.90M | 6.40M | 5.10M | 3.30M | 2.00M |
| EBITDA | -608.26M | -4.49B | 5.63B | 5.10B | 2.46B | 674.72M | 269.52M | 206.40M | 299.34M | 303.59M | 305.26M | 404.44M | 409.90M | 392.90M | 334.56M | 272.06M | 219.75M | 229.40M | 176.30M | 173.75M | 189.43M | 180.14M | 153.33M | 110.08M | 76.09M | 52.12M | 46.10M | 56.90M | 56.40M | 53.50M | 27.00M | 28.40M | 34.20M | 34.70M | 29.00M | 26.20M | 21.50M | 15.20M | 10.70M |
| EBITDA Ratio | -22.77% | 23.71% | 22.24% | 22.53% | 16.87% | 16.01% | 13.38% | 13.21% | 15.33% | 14.39% | 15.44% | 20.12% | 20.07% | 20.39% | 18.86% | 13.77% | 13.73% | 14.27% | 14.02% | 17.03% | 18.82% | 20.18% | 21.56% | 13.88% | 17.54% | 10.23% | 11.43% | 14.73% | 14.65% | 16.92% | 7.36% | 1.82% | 11.26% | 12.07% | 11.89% | 12.82% | 13.35% | 12.16% | 10.07% |
| Operating Income | 365.70M | 482.62M | 489.43M | 410.96M | 229.66M | -108.64M | 116.65M | 53.19M | 166.71M | 149.98M | 169.46M | 264.11M | 295.16M | 284.01M | 230.99M | 182.94M | 135.19M | 146.11M | 115.30M | 108.85M | 145.76M | 137.38M | 112.03M | 66.77M | 48.60M | 31.00M | 26.60M | 41.70M | 39.70M | 36.70M | 10.40M | 14.50M | 22.10M | 24.40M | 21.10M | 19.80M | 16.40M | 11.90M | 8.70M |
| Operating Income Ratio | 13.69% | 17.22% | 16.75% | 16.14% | 9.93% | -4.74% | 5.40% | 2.57% | 8.26% | 6.90% | 7.95% | 12.76% | 14.23% | 14.74% | 12.95% | 10.37% | 9.25% | 11.47% | 9.76% | 9.99% | 14.53% | 15.39% | 13.70% | 9.20% | 8.84% | 7.02% | 6.23% | 9.96% | 10.01% | 10.33% | 3.16% | 4.39% | 7.11% | 8.51% | 8.93% | 9.95% | 10.28% | 9.40% | 8.50% |
| Total Other Income/Expenses | -1.22B | -5.19B | 4.95B | 4.49B | 2.03B | 319.39M | -15.35M | -73.94M | -20.86M | -18.43M | -57.07M | -34.27M | -59.39M | -63.73M | -45.16M | -40.10M | -14.35M | -4.08M | -21.93M | -11.52M | -32.07M | -32.97M | -47.06M | -21.32M | -32.18M | 3.23M | -3.80M | -2.50M | -6.10M | -12.70M | -5.70M | 13.10M | -8.50M | -7.20M | -5.30M | -4.60M | -3.70M | -2.40M | -2.70M |
| Income Before Tax | -850.10M | -4.70B | 5.44B | 4.91B | 2.26B | 507.36M | 97.81M | 41.56M | 145.85M | 131.56M | 112.39M | 231.58M | 235.76M | 220.28M | 185.83M | 142.84M | 120.84M | 142.03M | 93.37M | 97.33M | 113.69M | 104.41M | 64.97M | 45.44M | 16.40M | 34.20M | 22.80M | 36.50M | 33.60M | 24.00M | 4.70M | 27.60M | 13.60M | 17.20M | 15.80M | 15.20M | 12.70M | 9.50M | 6.00M |
| Income Before Tax Ratio | -31.82% | -167.87% | 186.08% | 192.79% | 97.81% | 22.15% | 4.53% | 2.01% | 7.22% | 6.05% | 5.27% | 11.19% | 11.37% | 11.43% | 10.42% | 8.10% | 8.27% | 11.15% | 7.91% | 8.93% | 11.33% | 11.70% | 7.95% | 6.26% | 2.98% | 7.74% | 5.34% | 8.72% | 8.47% | 6.75% | 1.43% | 8.36% | 4.38% | 6.00% | 6.69% | 7.64% | 7.96% | 7.50% | 5.87% |
| Income Tax Expense | -212.78M | -1.08B | 1.19B | 1.10B | 502.41M | 146.36M | -16.94M | 13.44M | 32.75M | 42.71M | 34.57M | 62.28M | 57.74M | 33.35M | 36.67M | 44.58M | 26.55M | 38.76M | 15.79M | 31.04M | 37.52M | 36.54M | 20.79M | 13.63M | 4.70M | 9.90M | 6.40M | 9.10M | 8.40M | 8.40M | 1.90M | 12.00M | 5.40M | 6.50M | 5.70M | 5.70M | 5.00M | 3.40M | 1.70M |
| Net Income | -637.32M | -3.63B | 4.25B | 3.81B | 1.76B | 361.00M | 114.74M | 28.13M | 113.09M | 88.85M | 77.79M | 169.23M | 178.22M | 185.49M | 144.62M | 89.51M | 92.99M | 103.26M | 81.55M | 68.24M | 76.17M | 67.86M | 44.18M | 31.10M | 11.70M | 24.30M | 16.40M | 26.20M | 25.20M | 15.60M | 2.80M | 15.60M | 8.20M | 10.70M | 10.10M | 9.50M | 7.70M | 6.10M | 4.30M |
| Net Income Ratio | -23.86% | -129.45% | 145.57% | 149.83% | 76.08% | 15.76% | 5.31% | 1.36% | 5.60% | 4.08% | 3.65% | 8.18% | 8.60% | 9.63% | 8.11% | 5.07% | 6.36% | 8.11% | 6.91% | 6.26% | 7.59% | 7.60% | 5.40% | 4.28% | 2.13% | 5.50% | 3.84% | 6.26% | 6.35% | 4.39% | 0.85% | 4.72% | 2.64% | 3.73% | 4.27% | 4.78% | 4.83% | 4.82% | 4.20% |
| EPS | -21.82 | -121.79 | 142.61 | 127.86 | 58.93 | 12.10 | 4.12 | 0.88 | 3.74 | 3.08 | 2.72 | 5.85 | 6.39 | 6.70 | 5.28 | 3.30 | 3.48 | 3.92 | 3.13 | 2.65 | 3.00 | 2.70 | 1.79 | 1.27 | 0.49 | 0.99 | 0.67 | 1.07 | 1.03 | 0.64 | 0.12 | 0.66 | 0.35 | 0.46 | 0.45 | 0.42 | 0.34 | 0.28 | 0.22 |
| EPS Diluted | -21.82 | -121.79 | 140.83 | 126.20 | 58.27 | 11.94 | 4.07 | 0.88 | 3.71 | 3.05 | 2.69 | 5.78 | 6.29 | 6.59 | 5.20 | 3.24 | 3.41 | 3.83 | 3.06 | 2.58 | 2.90 | 2.61 | 1.74 | 1.27 | 0.48 | 0.99 | 0.66 | 1.05 | 1.03 | 0.64 | 0.12 | 0.66 | 0.35 | 0.46 | 0.45 | 0.42 | 0.34 | 0.28 | 0.22 |
| Weighted Avg Shares Out | 29.21M | 29.79M | 29.83M | 29.77M | 29.84M | 29.84M | 29.66M | 29.44M | 29.19M | 28.88M | 28.59M | 28.29M | 28.03M | 27.67M | 27.40M | 27.11M | 26.72M | 26.38M | 26.06M | 25.72M | 25.42M | 25.13M | 24.65M | 24.42M | 24.22M | 24.53M | 24.66M | 24.60M | 24.41M | 24.23M | 24.35M | 23.82M | 23.77M | 23.52M | 22.70M | 22.89M | 22.65M | 21.79M | 20.00M |
| Weighted Avg Shares Out (Dil) | 29.21M | 29.79M | 30.21M | 30.16M | 30.18M | 30.23M | 30.03M | 29.65M | 29.41M | 29.13M | 28.91M | 28.64M | 28.47M | 28.15M | 27.83M | 27.64M | 27.29M | 26.95M | 26.66M | 26.49M | 26.31M | 26.00M | 25.44M | 24.57M | 24.33M | 24.72M | 24.85M | 24.95M | 24.41M | 24.26M | 24.35M | 23.82M | 23.77M | 23.52M | 22.70M | 22.89M | 22.65M | 21.79M | 20.00M |
Reasons to Retain Bio-Rad (BIO) Stock in Your Portfolio Now
Bio-Rad's (BIO) robust digital PCR business and Clinical Diagnostics segments raise optimism. However, macro issues raise concerns.
BIO-key's PortalGuard Identity and Access Management Solution and Identity-Bound Biometrics Are Now Available on the Amazon Web Services (AWS) Marketplace
$BKYI BIO-key's PortalGuard Identity Access Management Solution & Identity-Bound Biometrics Are Now Available on the Amazon Web Services (AWS) Marketplace
BIO-key Reports Reduced Net Loss and Cash Used in Operations on Lower Q2'24 Revenues; Hosts Investor Call Thu. Aug. 15th at 10am ET
HOLMDEL, N.J., Aug. 14, 2024 (GLOBE NEWSWIRE) -- BIO-key ® International, Inc. (Nasdaq: BKYI), an innovative provider of workforce and customer Identity and Access Management (IAM) solutions featuring passwordless, phoneless and token-less Identity-Bound Biometric (IBB) authentication, announced results for its...
Bio-Rad (BIO) Faces Low BioPharma Demand, Competitive Pressure
Bio-Rad (BIO) is experiencing weaker sales in Asia as China is currently entangled in a challenging research funding environment, and Japan, too, is facing constrained funding issues.
Identity and Access Management Solutions Provider BIO-key Hosts Q2 Investor Call Thursday, August 15th at 10am ET
HOLMDEL, N.J., Aug. 12, 2024 (GLOBE NEWSWIRE) -- BIO-key International, Inc. (NASDAQ: BKYI), an innovative provider of Identity and Access Management and Identity-Bound Biometric solutions, will host its Q2 2024 investor call Thursday, August 15th at 10 a.m.
BIO-TECHNE RELEASES FOURTH QUARTER FISCAL 2024 RESULTS
MINNEAPOLIS , Aug. 7, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today reported its financial results for the fourth quarter ending June 30, 2024. Fourth Quarter FY2024 Highlights Fourth quarter organic revenue increased by 1% (2% reported) to $306.1 million.
BIO-TECHNE DECLARES DIVIDEND
MINNEAPOLIS , Aug. 7, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) announced that its Board of Directors has decided to pay a dividend of $0.08 per share for the quarter ended June 30, 2024. The quarterly dividend will be payable...
Bio-Rad (BIO) Q2 Earnings Surpass Estimates, Guidance Lowered
Bio-Rad (BIO) witnesses growth in the second quarter across the Clinical Diagnostics segment, primarily driven by an increased demand for quality control and blood typing products.
Bio-Rad Laboratories, Inc. (BIO) Q2 2024 Earnings Call Transcript
Bio-Rad Laboratories, Inc. (NYSE:BIO ) Q2 2024 Earnings Conference Call August 1, 2024 5:00 PM ET Company Participants Edward Chung - Vice President of Investor Relations Norman Schwartz - Chairman of the Board, President and CEO Andy Last - Executive...
Bio-Rad Laboratories (BIO) Surpasses Q2 Earnings Estimates
Bio-Rad Laboratories (BIO) came out with quarterly earnings of $3.11 per share, beating the Zacks Consensus Estimate of $2.12 per share. This compares to earnings of $3 per share a year ago.
Source: https://incomestatements.info
Category: Stock Reports